FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024273754> ?p ?o ?g. }

• W2024273754 endingPage "20445" @default.
• W2024273754 startingPage "20441" @default.
• W2024273754 abstract "Serpins form an enormous superfamily of 40–60-kDa proteins found in almost all types of organisms, including humans. Most are one-use suicide substrate serine and cysteine proteinase inhibitors that have evolved to finely regulate complex proteolytic pathways, such as blood coagulation, fibrinolysis, and inflammation. Despite distinct functions for each serpin, there is much redundancy in the primary specificity-determining residues. However, many serpins exploit additional exosites to generate the exquisite specificity that makes a given serpin effective only when certain other criteria, such as the presence of specific cofactors, are met. With a focus on human serpins, this minireview examines use of exosites by nine serpins in the initial complex-forming phase to modulate primary specificity in either binary serpin-proteinase complexes or ternary complexes that additionally employ a protein or other cofactor. A frequent theme is down-regulation of inhibitory activity unless the exosite(s) are engaged. In addition, the use of exosites by maspin and plasminogen activator inhibitor-1 to indirectly affect proteolytic processes is considered. Serpins form an enormous superfamily of 40–60-kDa proteins found in almost all types of organisms, including humans. Most are one-use suicide substrate serine and cysteine proteinase inhibitors that have evolved to finely regulate complex proteolytic pathways, such as blood coagulation, fibrinolysis, and inflammation. Despite distinct functions for each serpin, there is much redundancy in the primary specificity-determining residues. However, many serpins exploit additional exosites to generate the exquisite specificity that makes a given serpin effective only when certain other criteria, such as the presence of specific cofactors, are met. With a focus on human serpins, this minireview examines use of exosites by nine serpins in the initial complex-forming phase to modulate primary specificity in either binary serpin-proteinase complexes or ternary complexes that additionally employ a protein or other cofactor. A frequent theme is down-regulation of inhibitory activity unless the exosite(s) are engaged. In addition, the use of exosites by maspin and plasminogen activator inhibitor-1 to indirectly affect proteolytic processes is considered. Serpins are ubiquitously found in all multicellular organisms and even in some viruses and bacteria (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar, 2Steenbakkers P.J. Irving J.A. Harhangi H.R. Swinkels W.J. Akhmanova A. Dijkerman R. Jetten M.S. van der Drift C. Whisstock J.C. op den Kamp H.J. Mycol. Res. 2008; 112: 999-1006Crossref PubMed Scopus (27) Google Scholar). They are 40–60-kDa proteins present both extra- and intracellularly that function mostly as serine and cysteine proteinase inhibitors (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). Well known examples are antithrombin, the principal inhibitor of blood coagulation proteinases; PAI-1, 3The abbreviations used are: PAI-1plasminogen activator inhibitor-1tPAtissue-type plasminogen activatoruPAurokinase-type plasminogen activatorα1PIα1-proteinase inhibitorRCLreactive center loopfXafactor XaHCIIheparin cofactor IIZPIprotein Z-dependent proteinase inhibitorfIXafactor IXaPCIprotein C inhibitorPN1proteinase nexin-1GAGglycosaminoglycanIIathrombin. 3The abbreviations used are: PAI-1plasminogen activator inhibitor-1tPAtissue-type plasminogen activatoruPAurokinase-type plasminogen activatorα1PIα1-proteinase inhibitorRCLreactive center loopfXafactor XaHCIIheparin cofactor IIZPIprotein Z-dependent proteinase inhibitorfIXafactor IXaPCIprotein C inhibitorPN1proteinase nexin-1GAGglycosaminoglycanIIathrombin. an inhibitor of the plasminogen activators tPA and uPA; and α1PI, the principal inhibitor of neutrophil elastase. A characteristic of the processes regulated by these serpins is that they involve mostly proteinase cascades that need to be regulated with respect to both the site where they occur and their duration of action.Serpin Branched Pathway MechanismAll serpin structures determined so far have the same basic fold, composed of three major β-sheets, eight to nine α-helices, and an exposed reactive center loop (RCL) that contains the primary recognition site for attacking proteinases (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). Based on secondary structure predictions and the presence of ∼51 conserved, mostly interior residues, all serpins probably adopt this fold (3Irving J.A. Pike R.N. Lesk A.M. Whisstock J.C. Genome Res. 2000; 10: 1845-1864Crossref PubMed Scopus (505) Google Scholar). Extensive biochemical studies over the past 30 years have established that serpins inhibit proteinases by a branched pathway suicide substrate inhibition mechanism (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). RCL residues are recognized as a suitable substrate for an attacking proteinase, which binds to form an initial Michaelis-like complex (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). For serine and cysteine proteinases, substrate hydrolysis involves initial cleavage of the scissile bond and formation of an acyl ester (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). Most unusually, the serpin fold represents a metastable conformation. Consequently, upon cleavage of the scissile bond, the N-terminal portion of the cleaved RCL spontaneously and irreversibly inserts into β-sheet A as a middle strand through expansion of the sheet and, in so doing, drags the covalently linked proteinase to the bottom of the serpin (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar), where compression results in distortion of the active site and kinetic trapping of the covalent intermediate (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar, 4Dementiev A. Dobó J. Gettins P.G. J. Biol. Chem. 2006; 281: 3452-3457Abstract Full Text Full Text PDF PubMed Scopus (113) Google Scholar). The two competing branches of the pathway are thus (i) hydrolysis of the acyl intermediate to yield a cleaved serpin and free proteinase and (ii) kinetic trapping of the proteinase through translocation and concomitant distortion of the enzyme active site. Because such distortion requires only a covalent linkage between serpin and proteinase, the mechanism works for serine proteinases of both chymotrypsin and subtilisin folds and for cysteine proteinases of the caspase and cathepsin families. Because once started, loop insertion is essentially irreversible and rapid, the rate-determining step(s) for inhibition involve formation of the initial noncovalent Michaelis complex and/or the subsequent acylation step (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). This minireview focuses on this initial complex-forming phase.Primary Determinants of SpecificityGiven this serpin mechanism, it is not surprising that the primary specificity determinants are those at P1 and the immediately adjacent residues. The resulting interactions are thus very like those in noncovalent complexes of proteinases with Kunitz, Kazal, and Bowman-Birk inhibitors and involve backbone–backbone H-bonds between the RCL in extended β-conformation and the proteinase, and between the side chains of P1 and immediately adjacent residues with S1, S2, etc., pockets of the proteinase (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). In keeping with this, antithrombin, with Arg at P1, is an inhibitor of the Arg-specific proteinases IIa and fXa, and CrmA, with Asp at P1, is an inhibitor of caspases. Likewise, mutagenesis of the P1 Arg of antithrombin to Trp turns it into an effective chymotrypsin inhibitor (5Chuang Y.J. Swanson R. Raja S.M. Bock S.C. Olson S.T. Biochemistry. 2001; 40: 6670-6679Crossref PubMed Scopus (52) Google Scholar).Although there may be several potential cleavage sites within the RCL, only those that are 16–17 residues C-terminal from the exit point of the RCL from β-sheet A lead to successful proteinase inhibition. This arises directly from the physical restrictions imposed by the mechanism, which requires that the length of the loop that inserts into β-sheet A matches the length of the sheet so that the fully translocated proteinase is compressed against the bottom of the serpin. If the loop length is either too long or too short, the covalent intermediate is short-lived, presumably because active-site distortion is less severe and the proteinase less catalytically compromised (6Zhou A. Carrell R.W. Huntington J.A. J. Biol. Chem. 2001; 276: 27541-27547Abstract Full Text Full Text PDF PubMed Scopus (120) Google Scholar, 7Tesch L.D. Raghavendra M.P. Bedsted-Faarvang T. Gettins P.G. Olson S.T. Protein Sci. 2005; 14: 533-542Crossref PubMed Scopus (20) Google Scholar).For the 27 inhibitory human serpins, an astonishing 13 have Arg at P1, and two more have Lys (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). A similar pattern is also seen with Drosophila serpins, with 8 of 17 inhibitory members having P1 Arg or Lys (8Reichhart J.M. Trends Cell Biol. 2005; 15: 659-665Abstract Full Text Full Text PDF PubMed Scopus (88) Google Scholar). Despite human serpins showing a preponderance of basic residues at P1, they appear to have paradoxically high specificity for their cognate proteinases in vivo. Thus, fXa, which has very low substrate specificity beyond P1 (9Bianchini E.P. Louvain V.B. Marque P.E. Juliano M.A. Juliano L. Le Bonniec B.F. J. Biol. Chem. 2002; 277: 20527-20534Abstract Full Text Full Text PDF PubMed Scopus (62) Google Scholar), is inhibited by antithrombin under physiological conditions 4–5 orders of magnitude faster than by another P1 Arg-containing serpin, PAI-1. Conversely, under physiological conditions, HCII (P1 Leu) inhibits only the Arg-specific proteinase IIa (10Gettins P.G.W. Patston P.A. Olson S.T. Serpins: Structure, Function and Biology. R. G. Landes Co., Austin, TX1996Google Scholar), whereas ZPI (P1 Tyr) is a specific inhibitor of membrane-bound fXa (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar).Exosites Allow Refinement of SpecificityThe answer to how serpins show high specificity and a high rate of reaction in vivo while having the same P1 residue as many other serpins or else a seemingly inappropriate P1 residue is the use of one or more exosites on the serpin to refine the overall specificity and selectively enhance the reaction rate. This is facilitated by the length and flexibility of the exposed RCL such that a proteinase can simultaneously dock with the P1 residue within the RCL and an exosite elsewhere on the serpin. In addition, unstructured N- and C-terminal extensions on some serpins permit more remote serpin-proteinase interactions, whereas other serpin-proteinase pairs use a cofactor such as heparin or another protein to bring the two reactants together. Because each exosite can modify the overall binding affinity in the Michaelis complex and/or promote catalysis by locking the proteinase into a particular orientation with respect to the scissile bond, rate enhancements can be very large. Moreover, by tightening the Michaelis complex interaction, exosites can ensure that, once a serpin has bound to proteinase, its dissociation is slowed to an extent that commits it to undergoing acylation and conformational change steps that lead to proteinase trapping (11Izaguirre G. Swanson R. Raja S.M. Rezaie A.R. Olson S.T. J. Biol. Chem. 2007; 282: 33609-33622Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar, 12Johnson K.A. J. Biol. Chem. 2008; 283: 26297-26301Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar). As a result, most serpin-proteinase encounters proceed to a stable inhibited complex, causing the overall reaction rate to be limited by the rate of diffusional encounter between serpin and proteinase. A frequent overall theme is that, in the absence of the factor that refines the specificity, the serpin-proteinase reaction is deliberately suppressed. Only when full exosite engagement is effected does the rate reach the desired value. In this way, providing the exosite, or access to it, regulates whether or not the serpin will act on its target proteinase. This in turn allows not only specificity but also regulation in time and space by coordinately regulating the provision of the exosite.Exosite Interactions for Proteinase InhibitionTo date, nine inhibitory human serpins are known to employ one or more exosites. They do so in a variety of ways that involve either binary interaction with the target proteinase or ternary complex formation with another species.Binary ComplexesEven without an N- or C-terminal extension, some serpins can enhance the rate of proteinase inhibition using an already present exosite on the surface of the protein core. The best example is the inhibition of tPA by PAI-1, in which loop 37 near the active site interacts with residues in the distal portion of the RCL, including Glu at P4′ and P5′ (13Ibarra C.A. Blouse G.E. Christian T.D. Shore J.D. J. Biol. Chem. 2004; 279: 3643-3650Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar). These Glu residues enhance the rate of inhibition through a direct effect on Michaelis complex formation, with reductions of 13-fold in Michaelis complex formation and 5-fold in rate of inhibition upon replacement by Ala (13Ibarra C.A. Blouse G.E. Christian T.D. Shore J.D. J. Biol. Chem. 2004; 279: 3643-3650Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar). The importance of this loop is further illustrated in two related systems. In one, a IIa chimera in which its own loop 37 was replaced by that of tPA was inhibited by PAI-1 1000-fold faster (14Dekker R.J. Eichinger A. Stoop A.A. Bode W. Pannekoek H. Horrevoets A.J.G. J. Mol. Biol. 1999; 293: 613-627Crossref PubMed Scopus (25) Google Scholar). In the second, the snake Trimeresurus stejnegeri has used the opposite strategy of elimination of the loop-exosite interaction through shortening of loop 37 of its own plasminogen activator to slow down inhibition by the prey's PAI-1 and so promote an anticoagulant state (15Braud S. Le Bonniec B.F. Bon C. Wisner A. Biochemistry. 2002; 41: 8478-8484Crossref PubMed Scopus (23) Google Scholar). Another example is the inhibition of human neutrophil elastase by α1PI. This reaction has a rate constant of 6 × 107m−1 s−1 even though a peptide with the same P4-P4′ residues reacts 1000-fold slower (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). The involvement of an exosite was demonstrated by replacement of the whole of the RCL of α1-antichymotrypsin from P3 to P3′ with that of α1PI, which resulted in a rate constant for human neutrophil elastase inhibition of only 105m−1 s−1, i.e. 600-fold lower than the same residues in the context of α1PI (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar).An example of a more complex use of exosites is kallistatin, a specific inhibitor of tissue kallikreins. Kallistatin has a P1 Phe, despite the kallikrein targets being Arg-specific proteinases. However, Phe at P1 confers selectivity for kallikreins over other Arg-specific proteinases without undue loss of reactivity (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). This is due to a basic exosite between helix H and strand 2 of β-sheet C specifically enhancing the binding of kallikrein but not other Arg-specific proteinases (16Chen V.C. Chao L. Chao J. J. Biol. Chem. 2000; 275: 40371-49377Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar). Although this parallels the α1PI-human neutrophil elastase case described above, it is more sophisticated in that heparin can also bind to the exosite and block its availability to kallikrein, thereby acting as a negative regulator of kallistatin (17Chen V.C. Chao L. Pimenta D.C. Bledsoe G. Juliano L. Chao J. J. Biol. Chem. 2001; 276: 1276-1284Abstract Full Text Full Text PDF PubMed Scopus (50) Google Scholar).Regulation of the ability of plasmin to promote clot lysis should be most effective at the surface of the fibrin clot. α2-Antiplasmin achieves such site-specific inhibition of plasmin by using its N- and C-terminal extensions. The C-terminal extension specifically engages plasmin, using conserved Lys residues to engage the kringle domains of plasmin (18Frank P.S. Douglas J.T. Locher M. Llinás M. Schaller J. Biochemistry. 2003; 42: 1078-1085Crossref PubMed Scopus (31) Google Scholar) and to achieve a 30–60-fold rate enhancement to ∼2 × 107m−1 s−1. Consistent with this, the C-terminal extension lies close to the RCL such that the more distal conserved Lys residues can readily engage the kringle domains (19Law R.H. Sofian T. Kan W.T. Horvath A.J. Hitchen C.R. Langendorf C.G. Buckle A.M. Whisstock J.C. Coughlin P.B. Blood. 2008; 111: 2049-2052Crossref PubMed Scopus (32) Google Scholar). To efficiently inhibit plasmin that is close to the fibrin surface, α2-antiplasmin then makes use of its N-terminal tail, which contains a transglutamination site at residue 14 that allows covalent cross-linking to the fibrin surface by factor XIIIa (10Gettins P.G.W. Patston P.A. Olson S.T. Serpins: Structure, Function and Biology. R. G. Landes Co., Austin, TX1996Google Scholar).Ternary ComplexesThe quintessential example of a cofactor providing exosites to promote a specific serpin-proteinase interaction is the heparin-dependent reaction of antithrombin with blood coagulation proteinases. Here, heparin not only makes pre-existing exosites on the serpin more accessible to proteinases by allosterically activating the serpin, but itself provides exosites to bind and bring together the serpin and proteinase in a ternary bridging complex (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar, 20Izaguirre G. Zhang W. Swanson R. Bedsted T. Olson S.T. J. Biol. Chem. 2003; 278: 51433-51440Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar, 21Izaguirre G. Olson S.T. J. Biol. Chem. 2006; 281: 13424-13432Abstract Full Text Full Text PDF PubMed Scopus (36) Google Scholar).The antithrombin exosites become competent to bind two target proteinases, fIXa and fXa, when a specific heparin pentasaccharide binds to a basic site centered on helix D and conformationally activates the serpin (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). In the low activity state of antithrombin, which is the predominant form in plasma, favorable exosite interactions are offset by unfavorable interactions with the surface surrounding the RCL, which make it repulsive toward an approaching proteinase (22Huntington J.A. McCoy A. Belzar K.J. Pei X.Y. Gettins P.G. Carrell R.W. J. Biol. Chem. 2000; 275: 15377-15383Abstract Full Text Full Text PDF PubMed Scopus (70) Google Scholar, 23Whisstock J.C. Pike R.N. Jin L. Skinner R. Pei X.Y. Carrell R.W. Lesk A.M. J. Mol. Biol. 2000; 301: 1287-1305Crossref PubMed Scopus (82) Google Scholar). 4A. Dementiev, R. Roth, G. Isetti, S. T. Olson, and P. G. W. Gettins, manuscript in preparation. This repulsion is exacerbated by the burial of the RCL hinge in sheet A, which constrains the RCL to lie close to the serpin body. Heparin activation expels the RCL hinge from sheet A and also alters the surface H-bonding network, thereby reducing the repulsive interactions and favoring proteinase interaction with both the RCL and exosite determinants on strand 3 of β-sheet C just below the RCL (21Izaguirre G. Olson S.T. J. Biol. Chem. 2006; 281: 13424-13432Abstract Full Text Full Text PDF PubMed Scopus (36) Google Scholar).4 In this heparin-activated state, the exosite residues on antithrombin are positioned to specifically interact with basic residues of the autolysis loop of fXa and fIXa when the proteinases are bound to the serpin RCL (25Manithody C. Yang L. Rezaie A.R. Biochemistry. 2002; 41: 6780-6788Crossref PubMed Scopus (58) Google Scholar).Heparin further promotes binding through bridging exosite interactions involving the basic site on antithrombin and basic exosites on the proteinase that are conserved in fXa, fIXa, and IIa (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). Structures of the heparin-antithrombin-S195A/anhydro-IIa Michaelis complex show that the engagement of the serpin RCL with the proteinase active site aligns the heparin pentasaccharide-binding site on antithrombin with the basic exosite on the proteinase to allow heparin to bridge and stabilize the serpin-proteinase Michaelis complex (Fig. 1) (26Li W. Johnson D.J. Esmon C.T. Huntington J.A. Nat. Struct. Mol. Biol. 2004; 11: 857-862Crossref PubMed Scopus (303) Google Scholar, 27Dementiev A. Petitou M. Herbert J.M. Gettins P.G.W. Nat. Struct. Mol. Biol. 2004; 11: 863-867Crossref PubMed Scopus (125) Google Scholar). Serpin exosites and heparin-bridging exosites together ensure specific inhibition of the three target proteinases at physiological rates of 107–108m−1 s−1, representing a 103–105-fold increase (28Olson S.T. Swanson R. Raub-Segall E. Bedsted T. Sadri M. Petitou M. Hérault J.M. Björk I. Thromb. Haemost. 2004; 92: 929-939Crossref PubMed Scopus (111) Google Scholar). It is important, however, that for the Michaelis complex to proceed to the proteinase-translocated covalent complex it be destabilized once the acyl intermediate has formed. Here, the remarkable conformational change represented by RCL insertion into β-sheet A is critical because it reduces the affinity of antithrombin for heparin 1000-fold to cause dissociation from the heparin chain (Fig. 1) (10Gettins P.G.W. Patston P.A. Olson S.T. Serpins: Structure, Function and Biology. R. G. Landes Co., Austin, TX1996Google Scholar).The use of exosites rather than the RCL to determine specificity appears to have evolved for a purpose in the case of antithrombin. Thus, the P1 Arg bait is potentially capable of recognizing the anticoagulant proteinase, activated protein C, which shares a trypsin-like specificity for P1 Arg-containing substrates with the procoagulant proteinase targets of antithrombin. However, heparin-activated antithrombin inhibits activated protein C 107-fold slower than IIa, fXa, and fIXa. This poor reactivity results from the antithrombin RCL sequence antagonizing the binding of activated protein C (29Hopkins P.C. Pike R.N. Stone S.R. J. Mol. Evol. 2000; 51: 507-515Crossref PubMed Scopus (28) Google Scholar), consistent with the idea that the antithrombin RCL sequence evolved to prevent reaction with this anticoagulant proteinase.Protein C inhibitor (PCI) provides a contrasting example in which a P1 Arg, together with exosite determinants provided by a heparin or protein cofactor, is utilized to specifically inhibit two anticoagulant proteinases. Heparin promotes PCI inhibition of activated protein C by bridging the basic H helix of PCI and loop 70 of the proteinase (30Li W. Adams T.E. Nangalia J. Esmon C.T. Huntington J.A. Proc. Natl. Acad. Sci. U.S.A. 2008; 105: 4661-4666Crossref PubMed Scopus (53) Google Scholar). The endothelial cell receptor, thrombomodulin, transforms IIa into an anticoagulant proteinase and a target of PCI by acting as a bridging cofactor that binds to the basic H helix of PCI and loop 70 of IIa (exosite I) (30Li W. Adams T.E. Nangalia J. Esmon C.T. Huntington J.A. Proc. Natl. Acad. Sci. U.S.A. 2008; 105: 4661-4666Crossref PubMed Scopus (53) Google Scholar, 31Rezaie A.R. Yang L. Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 12051-12056Crossref PubMed Scopus (45) Google Scholar, 32Yang L. Manithody C. Walston T.D. Cooper S.T. Rezaie A.R. J. Biol. Chem. 2003; 278: 37465-37470Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar). In the absence of these cofactors, the positively charged cofactor-binding sites on the serpin and the proteinase antagonize their interaction because of their proximity to the binding interface. Interestingly, in the presence of heparin, PCI efficiently inhibits the procoagulant form of IIa that is not receptor-bound. Heparin again acts as a bridging cofactor to bind the basic helix H site in PCI, but instead of binding to exosite I of thrombin, it binds to exosite II, the same site used in heparin bridging of antithrombin and IIa. The ability of heparin to bridge through either exosite II in IIa or exosite I in activated protein C results from alternative modes of heparin binding to helix H (30Li W. Adams T.E. Nangalia J. Esmon C.T. Huntington J.A. Proc. Natl. Acad. Sci. U.S.A. 2008; 105: 4661-4666Crossref PubMed Scopus (53) Google Scholar). The two binding modes act to align either of the two proteinase exosites with the PCI helix H site with a common basic residue acting as a pivot for these alternative modes. Bridging heparin also enhances the reactivity of PN1 against both IIa and factor XIa, with ∼500-fold enhancement of the former (10Gettins P.G.W. Patston P.A. Olson S.T. Serpins: Structure, Function and Biology. R. G. Landes Co., Austin, TX1996Google Scholar) and 20-fold enhancement of the latter (33Knauer D.J. Majumdar D. Fong P.C. Knauer M.F. J. Biol. Chem. 2000; 275: 37340-37346Abstract Full Text Full Text PDF PubMed Scopus (52) Google Scholar).Two other serpins provide examples of an unfavorable P1 residue being used to prevent reaction with P1 Arg-specific proteinases, except for the desired target, through use of favorable exosite interactions. HCII is a specific IIa inhibitor despite having an unfavorable P1 Leu (10Gettins P.G.W. Patston P.A. Olson S.T. Serpins: Structure, Function and Biology. R. G. Landes Co., Austin, TX1996Google Scholar). Either of two GAG cofactors, heparin or dermatan sulfate, enables the serpin to specifically inhibit IIa at a physiological rate of ∼107m−1 s−1 (10Gettins P.G.W. Patston P.A. Olson S.T. Serpins: Structure, Function and Biology. R. G. Landes Co., Austin, TX1996Google Scholar). As with antithrombin, binding of the GAG to the serpin presents new exosites through both allosteric activation and bridging mechanisms (Fig. 1). GAG binding to overlapping basic sites in helix D of HCII allosterically activates the serpin by releasing the N-terminal acidic tail from an intramolecular interaction, possibly with the basic GAG-binding site, to promote exosite-exosite interactions between the tail and exosite I of IIa (10Gettins P.G.W. Patston P.A. Olson S.T. Serpins: Structure, Function and Biology. R. G. Landes Co., Austin, TX1996Google Scholar, 34Baglin T.P. Carrell R.W. Church F.C. Esmon C.T. Huntington J.A. Proc. Natl. Acad. Sci. U.S.A. 2002; 99: 11079-11084Crossref PubMed Scopus (184) Google Scholar). The GAGs may further stabilize the Michaelis complex by bridging the serpin and proteinase through exosite II of IIa. The two types of exosite interactions together position the P1 Leu to interact with the proteinase S1 binding pocket and to compensate for the preference for a P1 Arg (Fig. 1) (34Baglin T.P. Carrell R.W. Church F.C. Esmon C.T. Huntington J.A. Proc. Natl. Acad. Sci. U.S.A. 2002; 99: 11079-11084Crossref PubMed Scopus (184) Google Scholar).A second case of an unfavorable P1 residue is ZPI, which specifically inhibits fXa despite having a P1 Tyr (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). ZPI requires protein Z, phospholipid, and calcium ions to stabilize a protein Z-ZPI-fXa Michaelis complex on a procoagulant membrane surface through exosite-exosite interactions (35Huang X. Swanson R. Broze Jr., G.J. Olson S.T. J. Biol. Chem. 2008; 283: 29770-29783Abstract Full Text Full Text PDF PubMed Scopus (37) Google Scholar). The serpin circulates in plasma as a tight complex with its cofactor, protein Z (1Gettins P.G. Chem. Rev. 2002; 102: 4751-4804Crossref PubMed Scopus (979) Google Scholar). Interactions between their N-terminal Gla domains promote membrane-specific binding between protein Z and fXa (36Rezaie A.R. Bae J.S. Manithody C. Qureshi S.H. Yang L. J. Biol. Chem. 2008; 283: 19922-19926Abstract Full Text Full Text PDF PubMed Scopus (32) Google Scholar). These interactions juxtapose the C-terminal domains of protein Z and fXa, distal from the membrane surface, in a manner that presents the RCL P1 Tyr to the active site so as to overcome the unfavorable P1-S1 interaction (Fig. 1) (36Rezaie A.R. Bae J.S. Manithody C. Qureshi S.H. Yang L. J. Biol. Chem. 2008; 283: 19922-19926Abstract Full Text Full Text PDF PubMed Scopus (32) Google Scholar). Mutagenesis studies have suggested that additional serpin-proteinase exosite interactions further stabilize the membrane-associated Michaelis complex (Fig. 1) (37Rezaie A.R. Manithody C. Yang L. J. Biol. Chem. 2005; 280: 32722-32728Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar). Presumably, regulation of procoagulant membrane-bound fXa activity by the ZPI-protein Z complex is relevant to fXa bound in procoagulant complexes such as prothrombinase and fXase (38Han X. Fiehler R. Broze Jr., G.J. Blood. 2000; 96: 3049-3055Crossref PubMed Google Scholar). An important unanswered question concerns the role of the novel N-terminal acidic tail of ZPI in stabilizing the membrane-bound protein Z-ZPI-fXa Michaelis complex and potentially allowing ZPI to compete with prothrombin for fXa bound in the prothrombinase complex. As with the essential weakening of the antithrombin-heparin interaction following progression of the Michaelis complex t" @default.
• W2024273754 created "2016-06-24" @default.
• W2024273754 creator A5022122582 @default.
• W2024273754 creator A5055990354 @default.
• W2024273754 date "2009-07-01" @default.
• W2024273754 modified "2023-10-16" @default.
• W2024273754 title "Exosite Determinants of Serpin Specificity" @default.
• W2024273754 cites W1967232207 @default.
• W2024273754 cites W1969493437 @default.
• W2024273754 cites W1975013617 @default.
• W2024273754 cites W1976540012 @default.
• W2024273754 cites W1981554063 @default.
• W2024273754 cites W2002635586 @default.
• W2024273754 cites W2005121156 @default.
• W2024273754 cites W2008325045 @default.
• W2024273754 cites W2011955429 @default.
• W2024273754 cites W2015207544 @default.
• W2024273754 cites W2017171212 @default.
• W2024273754 cites W2018677458 @default.
• W2024273754 cites W2018798307 @default.
• W2024273754 cites W2024709755 @default.
• W2024273754 cites W2026938425 @default.
• W2024273754 cites W2028745592 @default.
• W2024273754 cites W2032615313 @default.
• W2024273754 cites W2039192169 @default.
• W2024273754 cites W2042092300 @default.
• W2024273754 cites W2042123088 @default.
• W2024273754 cites W2042447721 @default.
• W2024273754 cites W2043352206 @default.
• W2024273754 cites W2057382122 @default.
• W2024273754 cites W2058307008 @default.
• W2024273754 cites W2059305805 @default.
• W2024273754 cites W2065441127 @default.
• W2024273754 cites W2075334974 @default.
• W2024273754 cites W2076836490 @default.
• W2024273754 cites W2079171445 @default.
• W2024273754 cites W2079659761 @default.
• W2024273754 cites W2080718685 @default.
• W2024273754 cites W2082213605 @default.
• W2024273754 cites W2084063310 @default.
• W2024273754 cites W2086758849 @default.
• W2024273754 cites W2091305296 @default.
• W2024273754 cites W2094916717 @default.
• W2024273754 cites W2119978099 @default.
• W2024273754 cites W2122502632 @default.
• W2024273754 cites W2131956504 @default.
• W2024273754 cites W2141466802 @default.
• W2024273754 cites W2143749645 @default.
• W2024273754 cites W2160815497 @default.
• W2024273754 cites W2167040910 @default.
• W2024273754 cites W4229858997 @default.
• W2024273754 cites W4247682802 @default.
• W2024273754 cites W47882236 @default.
• W2024273754 doi "https://doi.org/10.1074/jbc.r800064200" @default.
• W2024273754 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2742806" @default.
• W2024273754 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19401470" @default.
• W2024273754 hasPublicationYear "2009" @default.
• W2024273754 type Work @default.
• W2024273754 sameAs 2024273754 @default.
• W2024273754 citedByCount "75" @default.
• W2024273754 countsByYear W20242737542012 @default.
• W2024273754 countsByYear W20242737542013 @default.
• W2024273754 countsByYear W20242737542014 @default.
• W2024273754 countsByYear W20242737542015 @default.
• W2024273754 countsByYear W20242737542016 @default.
• W2024273754 countsByYear W20242737542017 @default.
• W2024273754 countsByYear W20242737542018 @default.
• W2024273754 countsByYear W20242737542019 @default.
• W2024273754 countsByYear W20242737542020 @default.
• W2024273754 countsByYear W20242737542021 @default.
• W2024273754 countsByYear W20242737542022 @default.
• W2024273754 countsByYear W20242737542023 @default.
• W2024273754 crossrefType "journal-article" @default.
• W2024273754 hasAuthorship W2024273754A5022122582 @default.
• W2024273754 hasAuthorship W2024273754A5055990354 @default.
• W2024273754 hasBestOaLocation W20242737541 @default.
• W2024273754 hasConcept C104317684 @default.
• W2024273754 hasConcept C185592680 @default.
• W2024273754 hasConcept C2778965386 @default.
• W2024273754 hasConcept C54355233 @default.
• W2024273754 hasConcept C70721500 @default.
• W2024273754 hasConcept C86803240 @default.
• W2024273754 hasConceptScore W2024273754C104317684 @default.
• W2024273754 hasConceptScore W2024273754C185592680 @default.
• W2024273754 hasConceptScore W2024273754C2778965386 @default.
• W2024273754 hasConceptScore W2024273754C54355233 @default.
• W2024273754 hasConceptScore W2024273754C70721500 @default.
• W2024273754 hasConceptScore W2024273754C86803240 @default.
• W2024273754 hasIssue "31" @default.
• W2024273754 hasLocation W20242737541 @default.
• W2024273754 hasLocation W20242737542 @default.
• W2024273754 hasLocation W20242737543 @default.
• W2024273754 hasLocation W20242737544 @default.
• W2024273754 hasOpenAccess W2024273754 @default.
• W2024273754 hasPrimaryLocation W20242737541 @default.
• W2024273754 hasRelatedWork W1531601525 @default.
• W2024273754 hasRelatedWork W1990781990 @default.
• W2024273754 hasRelatedWork W2384464875 @default.

• next